Professor Ken Smith

Director, The Walter and Eliza Hall Institute of Medical Research

biography

Zhiwei Chen is a Tenured Chair Professor of Immunology and Immunotherapy in the Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong (HKU). He was conferred the Suen Chi-Sun Professorship in Clinical Science in 2024.

Prof. Chen received his PhD from New York University School of Medicine in 1996 and progressed from an NIH F32 Post-doctoral Fellow to Assistant Professor at the Aaron Diamond AIDS Research Center of the Rockefeller University from 1996 to 2002. In 2007, he joined HKU as an Associated Professor and the Founding Director of the HKUMed AIDS Institute. He was a former Chairman of the Hong Kong Society for Immunology and an Executive Committee Member of the China AIDS Vaccine Initiative. He also served as an Member of Hong Kong Advisory Council on AIDS for the HKSAR Department of Health from 2008 to 2014.

His research focuses on AIDS/SARS/COVID-19 pathogenesis and immunotherapy, with a particular emphasis on the early events of viral infection. He pioneered the creation of HKU-patented platforms of technologies, including the PD1-based vaccine, the tandem anti-HIV-1 bi-specific antibody, and an anti-Δ42PD1 antibody drug for the fight against viral infection and cancer. He has been ranked by Clarivate Analytics among the top 1% of researchers worldwide by citations and a Highly Cited Researcher in 2022, 2023 and 2024. He has won numerous research grants as PI from RGC GRF/CRF/TRS, ITC RAISe+, HMRF, NIH RO1, amfAR, the Bill & Melinda Gates Foundation, and so forth. He also won the HKU Knowledge Exchange Excellence Award 2019, Outstanding Researcher Award 2021 and Outstanding Research Student Supervisor Award 2021.

Title

Sustained cART-free HIV-1 control by immunotherapy: a tale from mouse/monkey to human

abstract

HIV/AIDS pandemic has resulted in 40.8 million people living with HIV-1 (PLWH) and 44.2 million deaths since 1981. In Hong Kong, despite active prevention and timely introduction of combination antiretroviral therapy (cART), the cumulative number of PLWH has increased to 12,905 in June 2026, requiring an estimated annual cART expense of HK$ 750 million. Since the life-long expensive cART is unlikely sustainable and does not cure HIV/AIDS, our objective is to determine effective immunotherapies that potentiate host immunity to achieve sustained cART-free HIV-1 control, a state of viral suppression below the limit of detection for a prolonged period in PLWH. With supports from RGC GRF/CRF/TRS grants, we have made some critical findings. First, we found that an PD1-based vaccine elicits high frequencies of cytotoxic CD8+ T lymphocytes (CTLs), which are essential for eliminating virus-infected cells. Monkeys pre-vaccinated with such a vaccine have shown sustained cART-free virologic control for over 8 years against a simian AIDS virus (SHIV). Second, we engineered a potent and broadly bi-specific neutralizing antibody BiIA-SG that eliminates virus in humanized mice and suppresses the virus in all monkeys in two post-exposure experiments. Importantly, we have finished a double-blind, placebo-controlled phase I trial on the human PD1-based vaccine ICVAX among PLWH with demonstrated safety and immunogenicity.  A follow-up IIT further revealed cART-free HIV-1 control for over 70 weeks in an ICVAX-treated patient. Our findings enrich the knowledge on mechanisms of immune protection critical for saving PLWH’s lives.